Measurable Residual Disease in AML

Abstract

Introduction Acute myeloid leukemia (AML) is a notoriously heterogeneous hematological malignancy with a relatively poor outcome depending on the risk classification, which is determined by white blood cell count (WBC), age, cytogenetics, and specific mutations.1 Although the majority of patients achieve a morphological complete remission (CR, defined as